A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 as an Adjunct to Antidepressant Therapies in the Treatment of Subjects With Generalized Anxiety Disorder Who Have Had an Inadequate Response to Antidepressant Therapies
Latest Information Update: 30 Jul 2025
At a glance
- Drugs Desmethyl cariprazine prodrug (Primary)
- Indications Generalised anxiety disorder
- Focus Adverse reactions; Therapeutic Use
- Sponsors AbbVie
Most Recent Events
- 13 May 2025 Status changed from not yet recruiting to recruiting.
- 03 Mar 2025 New trial record